We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Field Evaluation of Quantitative G6PD Diagnostics Reviewed

By LabMedica International staff writers
Posted on 27 Sep 2017
Print article
Image: The qualitative point-of-care test CareStart G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample. Panel A, no color change for sample with deficient G6PD enzymatic activity; Panel B, distinct purple color for sample with normal G6PD enzymatic activity (Photo courtesy of Access Bio).
Image: The qualitative point-of-care test CareStart G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample. Panel A, no color change for sample with deficient G6PD enzymatic activity; Panel B, distinct purple color for sample with normal G6PD enzymatic activity (Photo courtesy of Access Bio).
Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common enzymopathy with at least 400 million individuals affected worldwide. More than 185 clinically relevant variants of G6PDd have been reported with a spectrum of associated enzyme deficiencies.

The presence of G6PDd in patients with Plasmodium vivax infection results in significant challenges to achieving radical cure. The 8-aminoquinolone compounds are the only class of anti-malarial drugs currently available to eliminate the dormant hypnozoites liver stages of P. vivax are and these cause hemolysis in G6PDd individuals.

Scientists at the Charles Darwin University (Sydney, Australia) and their colleagues reviewed the methods for the field evaluation of quantitative G6PD diagnostics. G6PD enzyme activity and its degradation is temperature dependent, hence whole EDTA blood should not be stored at room temperature. Freezing samples and maintaining a respective cold chain in a field setting is demanding and often impossible. Whole blood samples can be stored at 4–8 °C for later analysis; however the duration at which samples can be stored and reliably assayed at a later time point is unknown. Field evaluation is based on the comparison of paired samples, including one sample tested by the new assay at point of care and one sample tested by the gold-standard reference method, UV spectrophotometry in an established laboratory.

In one study the G6PD activity of paired samples collected from venous and capillary sampling were similar when measured by spectrophotometry, the medians were 7.51 and 7.61 U/gHb, respectively. Similarly, an evaluation of qualitative tests by fluorescent spot test (FST) and Carestart G6PD RDT showed 100% concordance between paired capillary and venous samples. ACCESS BIO has recently developed a Biosensor, a quantitative handheld device that measures G6PD activity based on the electrochemical properties of G6PD in blood samples.

The WST8/1-methoxy PMS test is a robust and cost effective alternative to estimate G6PD activity that can be performed on dried blood spots and whole blood samples. The WST8/1 test is based on the formation of an orange formazan dye generated by G6PD enzyme activity and facilitated by the 1-methoxy PMS as an electron carrier. The assay has been adapted for quantitative batch testing in a 96 well microplate and can be read by an enzyme-linked immunosorbent assay (ELISA) reader.

The authors concluded that their review presented a number of recommendations to facilitate standardized evaluation of quantitative G6PD activity test assays. Standardized evaluation studies are necessary to provide a comparable basis for subsequent pooled analyses. As novel quantitative G6PD diagnostics become available their potential to provide robust quantitative G6PD results suitable for field deployment needs to be assessed. The most recent generation of instruments contain an integrated temperature correction factor and hemoglobin measurement and G6PD activity is displayed normalized as U/gHb. The study was published on September 11, 2017, in the Malaria Journal.

Related Links:
Charles Darwin University


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.